The influence of neurotrophic factors treatment on stroke volume
Background. Cerebrolysin is a multimodal drug, with pleiotropic neuroprotective effects that simultaneously promotes neuroprotection while retaining the ability to influence neuroplasticity. Cerebrolysin is approved for the treatment of stroke, traumatic brain injury and cognitive dysfunction. Meth...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Amaltea Medical Publishing House
2013-09-01
|
| Series: | Romanian Journal of Neurology |
| Subjects: | |
| Online Access: | https://rjn.com.ro/articles/2013.3/RJN_2013_3_Art-04.pdf |
| _version_ | 1817981623321231360 |
|---|---|
| author | Adina Dora Stan Alexandru Badisor Codruta Birle Alina Vasilica Blesneag Iulian Opincariu Mihaela Iancu Dana Racasan Dafin Fior Muresanu |
| author_facet | Adina Dora Stan Alexandru Badisor Codruta Birle Alina Vasilica Blesneag Iulian Opincariu Mihaela Iancu Dana Racasan Dafin Fior Muresanu |
| author_sort | Adina Dora Stan |
| collection | DOAJ |
| description | Background. Cerebrolysin is a multimodal drug, with pleiotropic neuroprotective effects that simultaneously promotes neuroprotection while retaining the ability to influence neuroplasticity. Cerebrolysin is approved for the treatment of stroke, traumatic brain injury and cognitive dysfunction.
Methods. A randomized, double-blind, placebo-controlled clinical trial was conducted in sixty patients with acute supratentorial ischemic stroke. The patients were randomized to either Cerebrolysin 30 ml/day (n = 30) or placebo (n = 30) in a 1:1 manner. The treatment period was 10 days. Stroke volume was measured in the first 24 hours after stroke onset using diffusion-weighted images, and it was measured again at 30 days after stroke using fluid attenuated inversion recovery images.
Results. A significant reduction of stroke volume at 30 days was demonstrated in both Cerebrolysin- and placebotreated patients (p < 0.001). Although it was not statistically significant a better response in stroke volume reduction was observed in the Cerebrolysin-treated group, compared to the placebo group (Mann Whitney test, U = 426, p = 0.723, mean rank, 29.70 vs. 31,30).
Interpretation. We demonstrated a positive effect from Cerebrolysin treatment to reduce ischemic stroke volume. |
| first_indexed | 2024-04-13T23:09:52Z |
| format | Article |
| id | doaj.art-8eca35bf3e004f6e8cbaa75095f01a33 |
| institution | Directory Open Access Journal |
| issn | 1843-8148 2069-6094 |
| language | English |
| last_indexed | 2024-04-13T23:09:52Z |
| publishDate | 2013-09-01 |
| publisher | Amaltea Medical Publishing House |
| record_format | Article |
| series | Romanian Journal of Neurology |
| spelling | doaj.art-8eca35bf3e004f6e8cbaa75095f01a332022-12-22T02:25:36ZengAmaltea Medical Publishing HouseRomanian Journal of Neurology1843-81482069-60942013-09-0112312412910.37897/RJN.2013.3.4The influence of neurotrophic factors treatment on stroke volumeAdina Dora Stan0Alexandru Badisor1Codruta Birle2Alina Vasilica Blesneag3Iulian Opincariu4Mihaela Iancu5Dana Racasan6Dafin Fior Muresanu7University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca, Neurology DepartmentEmergency County Hospital Cluj-Napoca, Neurology DepartmentUniversity of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca, Neurology DepartmentUniversity of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca, Neurology DepartmentUniversity of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca, Radiology DepartmentUniversity of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca, Department of Medical Informatics and BiostaticsEmergency County Hospital Cluj-Napoca, Neurology DepartmentUniversity of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca, Neurology DepartmentBackground. Cerebrolysin is a multimodal drug, with pleiotropic neuroprotective effects that simultaneously promotes neuroprotection while retaining the ability to influence neuroplasticity. Cerebrolysin is approved for the treatment of stroke, traumatic brain injury and cognitive dysfunction. Methods. A randomized, double-blind, placebo-controlled clinical trial was conducted in sixty patients with acute supratentorial ischemic stroke. The patients were randomized to either Cerebrolysin 30 ml/day (n = 30) or placebo (n = 30) in a 1:1 manner. The treatment period was 10 days. Stroke volume was measured in the first 24 hours after stroke onset using diffusion-weighted images, and it was measured again at 30 days after stroke using fluid attenuated inversion recovery images. Results. A significant reduction of stroke volume at 30 days was demonstrated in both Cerebrolysin- and placebotreated patients (p < 0.001). Although it was not statistically significant a better response in stroke volume reduction was observed in the Cerebrolysin-treated group, compared to the placebo group (Mann Whitney test, U = 426, p = 0.723, mean rank, 29.70 vs. 31,30). Interpretation. We demonstrated a positive effect from Cerebrolysin treatment to reduce ischemic stroke volume.https://rjn.com.ro/articles/2013.3/RJN_2013_3_Art-04.pdfmri stroke volumecerebrolysinneuroprotection |
| spellingShingle | Adina Dora Stan Alexandru Badisor Codruta Birle Alina Vasilica Blesneag Iulian Opincariu Mihaela Iancu Dana Racasan Dafin Fior Muresanu The influence of neurotrophic factors treatment on stroke volume Romanian Journal of Neurology mri stroke volume cerebrolysin neuroprotection |
| title | The influence of neurotrophic factors treatment on stroke volume |
| title_full | The influence of neurotrophic factors treatment on stroke volume |
| title_fullStr | The influence of neurotrophic factors treatment on stroke volume |
| title_full_unstemmed | The influence of neurotrophic factors treatment on stroke volume |
| title_short | The influence of neurotrophic factors treatment on stroke volume |
| title_sort | influence of neurotrophic factors treatment on stroke volume |
| topic | mri stroke volume cerebrolysin neuroprotection |
| url | https://rjn.com.ro/articles/2013.3/RJN_2013_3_Art-04.pdf |
| work_keys_str_mv | AT adinadorastan theinfluenceofneurotrophicfactorstreatmentonstrokevolume AT alexandrubadisor theinfluenceofneurotrophicfactorstreatmentonstrokevolume AT codrutabirle theinfluenceofneurotrophicfactorstreatmentonstrokevolume AT alinavasilicablesneag theinfluenceofneurotrophicfactorstreatmentonstrokevolume AT iulianopincariu theinfluenceofneurotrophicfactorstreatmentonstrokevolume AT mihaelaiancu theinfluenceofneurotrophicfactorstreatmentonstrokevolume AT danaracasan theinfluenceofneurotrophicfactorstreatmentonstrokevolume AT dafinfiormuresanu theinfluenceofneurotrophicfactorstreatmentonstrokevolume AT adinadorastan influenceofneurotrophicfactorstreatmentonstrokevolume AT alexandrubadisor influenceofneurotrophicfactorstreatmentonstrokevolume AT codrutabirle influenceofneurotrophicfactorstreatmentonstrokevolume AT alinavasilicablesneag influenceofneurotrophicfactorstreatmentonstrokevolume AT iulianopincariu influenceofneurotrophicfactorstreatmentonstrokevolume AT mihaelaiancu influenceofneurotrophicfactorstreatmentonstrokevolume AT danaracasan influenceofneurotrophicfactorstreatmentonstrokevolume AT dafinfiormuresanu influenceofneurotrophicfactorstreatmentonstrokevolume |